基于网络药理学的参桂胶囊治疗2型糖尿病作用机制研究  

Network pharmacology-based prediction of mechanism in Shengui capsule on type 2 diabetes mellitus

作　　者：周新凤 宋佳音 王丹[2] 杨子君 刘甜甜 崔妍 吴晓辉[1] ZHOU Xin-feng;SONG Jia-yin;WANG Dan;YANG Zi-jun;LIU Tian-tian;CUI Yan;WU Xiao-hui(Department of Clinical Pharmacy,College of Pharmacy,Tianjin Medical University,Tianjin 300070,China;Pharmacy Department,Chu Hsien-I Memorial Hospital,Tianjin Medical University,Tianjin 300134,China;Department of Pathogen Biology,School of Basic Medical Sciences,Tianjin Medical University,Tianjin 300070,China)

机构地区：[1]天津医科大学药学院临床药学系,天津300070 [2]天津医科大学朱宪彝纪念医院药剂科,天津300134 [3]天津医科大学基础医学院病原生物学系,天津300070

出　　处：《天津医科大学学报》2023年第1期21-26,40,共7页Journal of Tianjin Medical University

基　　金：天津市自然科学基金重点项目(19JCZDJC33500)。

摘　　要：目的:通过网络药理学研究参桂胶囊(SGC)治疗2型糖尿病(T2DM)的作用机制。方法:使用中药系统药理学分析平台(TCMSP)检索SGC中的主要活性成分及靶点,治疗靶标数据库(TTD)、比较毒性基因组学数据库(CTD)、在线孟德尔遗传(OMIM)、GeneCards数据库获取T2DM靶点,进而筛选出中药和疾病的共同靶点。采用Cytoscape3.8.2软件构建“成分-靶点”网络图,并通过Metascape对共同靶点进行GO和KEGG富集分析预测SGC主要作用通路。结果:分析显示SGC中的人参皂苷、咖啡酸、油酸、肉桂醛和β-谷甾醇为主要活性成分,核心靶点有胰岛素(INS)、白细胞介素-6(IL-6)、肿瘤坏死因子(TNF)、过氧化物酶体增殖物激活受体-γ(PPAR-γ)等。主要涉及低氧诱导因子-1(HIF-1)、晚期糖基化终末产物(AGE)-糖基化终末产物受体(RAGE)信号通路、c AMP信号通路等。结论:揭示了SGC可通过“多成分、多靶点、多途径”作用机制对抗T2DM,为今后研究SGC治疗T2DM提供了文献依据。Objective:To predict the mechanism of Shengui capsule(SGC) in the treatment of type 2 diabetes mellitus(T2DM)by network pharmacology method. Methods:The main active ingredients and their targets of SGC were searched by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP). Therapeutic Target Database(TTD),Comparative Toxicogenomics Database(CTD),Online Mendelian Inheritance in Man(OMIM)and GeneCards were used to obtain the related targets of T2DM,then the common targets of traditional Chinese medicine and disease were screened out. The "ingredients-target" network diagram was constructed with Cytoscape3.8.2 software. GO and KEGG enrichment analysis were performed on the common targets by Metascape to predict the main pathway of SGC. Results:Analysis showed that ginsenoside,caffeic acid,oleic acid,cinnamaldehyde and β-sitosterol were the main active ingredients in SGC,and the core targets were insulin(INS),interleukin-6(IL6),tumor necrosis factor(TNF),peroxisome proliferator-activated receptor gamma(PPARG),etc. It mainly involved hypoxia-inducible factor-1(HIF-1),advanced glycation end product(AGE)-glycation end product receptor(RAGE)signaling pathway,cyclic adenosine monophosphate(cAMP)signaling pathway,etc. Conclusion:This study reveals the "multi-ingredient,multi-target and multi-pathway" mechanism of SGC against T2DM,which provides a literature basis for the future study of SGC in the treatment of T2DM.

关 键 词：参桂胶囊 网络药理学 2型糖尿病 活性成分 

分 类 号：R781.4[医药卫生—口腔医学]